Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDAMA exclusivity provisions could be fulfilled by one pediatric clinical study -- NDMA.

This article was originally published in The Tan Sheet

Executive Summary

FDAMA EXCLUSIVITY FULFILLMENT WITH ONE PEDIATRIC CLINICAL STUDY is recommended by the Nonprescription Drug Manufacturers Association in April 15 comments to FDA on the draft list of approved drugs for which additional information may support health benefits in the pediatric population. "We believe that one adequately designed and well-controlled clinical study (as described above), or other clinical exposure in children not previously contemplated under FDA's prior rule, should be sufficient to fulfill the FDAMA exclusivity provisions on pediatric studies and that Rx and OTC drugs should be treated equally in this regard," NDMA maintains. "We ask FDA to affirm these points."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel